SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2004
CORAUTUS GENETICS INC.
(Exact Name Of Registrant As Specified In Charter)
| Delaware | | 0-27264 | | 33-0687976 |
| (State of Incorporation) | | (Commission File No.) | | (I.R.S. Employer Identification No.) |
75 Fifth Street, Suite 313
Atlanta, Georgia 30308
(Address of principal executive offices, including zip code)
(404) 526-6200
(Registrant’s telephone number, including area code)
Item 5. Other Events
On January 21, 2004, Corautus Genetics Inc. issued a news release, attached hereto as Exhibit 99.1, announcing that it had completed raising an additional $5,260,680 of equity to fund its upcoming Phase IIb clinical trial through the sale of 1,200,000 shares of common stock.
| Item | 7. Financial Statements and Exhibits |
Exhibit
Number
| | Description
|
99.1 | | Press Release dated January 21, 2004. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | Corautus Genetics Inc. |
| | | |
| Date: January 23, 2004 | | | | By: | | /s/ Jack W. Callicutt |
| | | | | |
|
| | | | | | | | | Jack W. Callicutt Vice President—Finance and Administration, Chief Accounting Officer and Assistant Secretary |
